Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Apparent Pacer Spikes in a Patient with Back and Chest Pain.

Lulla A, Griffey RT.

Clin Pract Cases Emerg Med. 2019 Feb 26;3(2):164-165. doi: 10.5811/cpcem.2019.1.41095. eCollection 2019 May. No abstract available.

2.

EMS, Emergency Medical Treatment and Active Labor Act, USA.

Lulla A, Svancarek B.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Mar 14.

3.

Gut Microbiota Composition and Blood Pressure.

Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR Jr, Shikany JM, Lloyd-Jones DM, Launer LJ, Fodor AA, Meyer KA.

Hypertension. 2019 May;73(5):998-1006. doi: 10.1161/HYPERTENSIONAHA.118.12109.

PMID:
30905192
4.

ONC201: a new treatment option being tested clinically for recurrent glioblastoma.

Ralff MD, Lulla AR, Wagner J, El-Deiry WS.

Transl Cancer Res. 2017 Oct;6(Suppl 7):S1239-S1243. doi: 10.21037/tcr.2017.10.03.

5.

Bcl-2 Protein Targeting by the p53/p21 Complex-Letter.

Hernandez Borrero LJ, Sikder R, Lulla A, Gokare P, Del Valle PR, Tian X, Zhang S, Abbosh PH, El-Deiry WS.

Cancer Res. 2018 May 15;78(10):2770-2771. doi: 10.1158/0008-5472.CAN-17-2556. Epub 2018 Apr 27. No abstract available.

6.

Mutation of CD2AP and SH3KBP1 Binding Motif in Alphavirus nsP3 Hypervariable Domain Results in Attenuated Virus.

Mutso M, Morro AM, Smedberg C, Kasvandik S, Aquilimeba M, Teppor M, Tarve L, Lulla A, Lulla V, Saul S, Thaa B, McInerney GM, Merits A, Varjak M.

Viruses. 2018 Apr 27;10(5). pii: E226. doi: 10.3390/v10050226.

7.

Timeliness of Proteolytic Events Is Prerequisite for Efficient Functioning of the Alphaviral Replicase.

Lulla V, Karo-Astover L, Rausalu K, Saul S, Merits A, Lulla A.

J Virol. 2018 Jun 29;92(14). pii: e00151-18. doi: 10.1128/JVI.00151-18. Print 2018 Jul 15.

8.

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.

Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS.

Mol Cancer Res. 2018 May;16(5):754-766. doi: 10.1158/1541-7786.MCR-17-0614. Epub 2018 Mar 27.

9.

Role of Dopamine Receptors in the Anticancer Activity of ONC201.

Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS.

Neoplasia. 2018 Jan;20(1):80-91. doi: 10.1016/j.neo.2017.10.002. Epub 2017 Dec 5.

10.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

11.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS.

Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.

12.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS.

Cancer Res. 2017 Dec 15;77(24):6902-6913. doi: 10.1158/0008-5472.CAN-17-1767. Epub 2017 Oct 23.

13.

Commentary.

Liang SY, Lulla A.

Ann Emerg Med. 2017 Oct;70(4):578-579. doi: 10.1016/j.annemergmed.2017.07.480. No abstract available.

PMID:
28946977
14.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.

15.

MMR-deficiency and BRCA2/EGFR/NTRK mutations.

Gokare P, Lulla AR, El-Deiry WS.

Aging (Albany NY). 2017 Aug 3;9(8):1849-1850. doi: 10.18632/aging.101275. No abstract available.

16.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.

PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.

17.

CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA.

Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS.

Cell Cycle. 2018;17(5):557-567. doi: 10.1080/15384101.2017.1346762. Epub 2018 Feb 19.

18.

The use of thrombolytics in the management of complex pleural fluid collections.

Heimes J, Copeland H, Lulla A, Duldulao M, Bahjri K, Zaheer S, Wallen JM.

J Thorac Dis. 2017 May;9(5):1310-1316. doi: 10.21037/jtd.2017.04.56.

19.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.

Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10.

20.

Role of Ultrasound in the Identification of Longitudinal Axis in Soft-Tissue Foreign Body Extraction.

Lulla A, Whitman T, Amii R, Chiem AT.

West J Emerg Med. 2016 Nov;17(6):819-821. Epub 2016 Sep 29.

21.

Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos.

Lulla A, Barnhill L, Bitan G, Ivanova MI, Nguyen B, O'Donnell K, Stahl MC, Yamashiro C, Klärner FG, Schrader T, Sagasti A, Bronstein JM.

Environ Health Perspect. 2016 Nov;124(11):1766-1775. Epub 2016 Jun 15.

22.

Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.

Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, Lulla A, Lulla V, Saul S, Nelander S, Dimberg A, Merits A, Leja-Jarblad J, Essand M.

Clin Cancer Res. 2017 Mar 15;23(6):1519-1530. doi: 10.1158/1078-0432.CCR-16-0925. Epub 2016 Sep 16.

23.

Discovery and clinical introduction of first-in-class imipridone ONC201.

Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.

Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review.

24.

Correction for Utt et al., Mutations Conferring a Noncytotoxic Phenotype on Chikungunya Virus Replicons Compromise Enzymatic Properties of Nonstructural Protein 2.

Utt A, Das PK, Varjak M, Lulla V, Lulla A, Merits A.

J Virol. 2016 Aug 12;90(17):8030. doi: 10.1128/JVI.01167-16. Print 2016 Sep 1. No abstract available.

25.

Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.

Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P.

J Virol. 2016 Jul 27;90(16):7405-7414. doi: 10.1128/JVI.00548-16. Print 2016 Aug 15.

26.

Wolbachia Blocks Viral Genome Replication Early in Infection without a Transcriptional Response by the Endosymbiont or Host Small RNA Pathways.

Rainey SM, Martinez J, McFarlane M, Juneja P, Sarkies P, Lulla A, Schnettler E, Varjak M, Merits A, Miska EA, Jiggins FM, Kohl A.

PLoS Pathog. 2016 Apr 18;12(4):e1005536. doi: 10.1371/journal.ppat.1005536. eCollection 2016 Apr. Erratum in: PLoS Pathog. 2016 May;12(5):e1005639.

27.

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

Prabhu VV, Hong B, Allen JE, Zhang S, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Res. 2016 Apr 1;76(7):1989-99. doi: 10.1158/0008-5472.CAN-14-2430. Epub 2016 Jan 12.

28.

Detection of Persistent Chikungunya Virus RNA but not Infectious Virus in Experimental Vertical Transmission in Aedes aegypti from Malaysia.

Wong HV, Vythilingam I, Sulaiman WY, Lulla A, Merits A, Chan YF, Sam IC.

Am J Trop Med Hyg. 2016 Jan;94(1):182-6. doi: 10.4269/ajtmh.15-0318. Epub 2015 Nov 23.

29.

Correction for Chen et al., Bindarit, an Inhibitor of Monocyte Chemotactic Protein Synthesis, Protects against Bone Loss Induced by Chikungunya Virus Infection.

Chen W, Foo SS, Taylor A, Lulla A, Merits A, Hueston L, Forwood MR, Walsh NC, Sims NA, Herrero LJ, Mahalingam S.

J Virol. 2015 Dec;89(23):12232. doi: 10.1128/JVI.02114-15. No abstract available.

30.

Heme oxygenase-1 protects endothelial cells from the toxicity of air pollutant chemicals.

Lawal A, Zhang M, Dittmar M, Lulla A, Araujo JA.

Toxicol Appl Pharmacol. 2015 May 1;284(3):281-291. doi: 10.1016/j.taap.2015.01.010. Epub 2015 Jan 22.

31.

Mutations conferring a noncytotoxic phenotype on chikungunya virus replicons compromise enzymatic properties of nonstructural protein 2.

Utt A, Das PK, Varjak M, Lulla V, Lulla A, Merits A.

J Virol. 2015 Mar;89(6):3145-62. doi: 10.1128/JVI.03213-14. Epub 2014 Dec 31. Erratum in: J Virol. 2016 Aug 12;90(17 ):8030.

32.

Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.

Her Z, Teng TS, Tan JJ, Teo TH, Kam YW, Lum FM, Lee WW, Gabriel C, Melchiotti R, Andiappan AK, Lulla V, Lulla A, Win MK, Chow A, Biswas SK, Leo YS, Lecuit M, Merits A, Rénia L, Ng LF.

EMBO Mol Med. 2015 Jan;7(1):24-41. doi: 10.15252/emmm.201404459.

33.

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.

Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B.

F1000Res. 2014 Aug 19;3:198. doi: 10.12688/f1000research.4340.1. eCollection 2014. Review.

34.

Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Chen W, Foo SS, Taylor A, Lulla A, Merits A, Hueston L, Forwood MR, Walsh NC, Sims NA, Herrero LJ, Mahalingam S.

J Virol. 2015 Jan;89(1):581-93. doi: 10.1128/JVI.02034-14. Epub 2014 Oct 22. Erratum in: J Virol. 2015 Dec 1;89(23):12232.

35.

Prime-boost immunization strategies against Chikungunya virus.

Hallengärd D, Lum FM, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.

36.

Characterization of Aedes aegypti innate-immune pathways that limit Chikungunya virus replication.

McFarlane M, Arias-Goeta C, Martin E, O'Hara Z, Lulla A, Mousson L, Rainey SM, Misbah S, Schnettler E, Donald CL, Merits A, Kohl A, Failloux AB.

PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2994. doi: 10.1371/journal.pntd.0002994. eCollection 2014 Jul.

37.

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG.

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. No abstract available.

PMID:
25005244
38.

Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity.

O'Donnell KC, Lulla A, Stahl MC, Wheat ND, Bronstein JM, Sagasti A.

Dis Model Mech. 2014 May;7(5):571-82. doi: 10.1242/dmm.013185. Epub 2014 Mar 13.

39.

Functional cross-talk between distant domains of chikungunya virus non-structural protein 2 is decisive for its RNA-modulating activity.

Das PK, Merits A, Lulla A.

J Biol Chem. 2014 Feb 28;289(9):5635-53. doi: 10.1074/jbc.M113.503433. Epub 2014 Jan 9.

40.

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P.

J Virol. 2014 Mar;88(5):2858-66. doi: 10.1128/JVI.03453-13. Epub 2013 Dec 26.

41.

Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine.

Lulla A, Reznik S, Trombetta L, Billack B.

J Appl Toxicol. 2014 Dec;34(12):1373-8. doi: 10.1002/jat.2969. Epub 2013 Dec 17.

PMID:
24347431
42.

RIG-I and MDA-5 detection of viral RNA-dependent RNA polymerase activity restricts positive-strand RNA virus replication.

Nikonov A, Mölder T, Sikut R, Kiiver K, Männik A, Toots U, Lulla A, Lulla V, Utt A, Merits A, Ustav M.

PLoS Pathog. 2013;9(9):e1003610. doi: 10.1371/journal.ppat.1003610. Epub 2013 Sep 5.

43.

Magnetic fractionation and proteomic dissection of cellular organelles occupied by the late replication complexes of Semliki Forest virus.

Varjak M, Saul S, Arike L, Lulla A, Peil L, Merits A.

J Virol. 2013 Sep;87(18):10295-312. doi: 10.1128/JVI.01105-13. Epub 2013 Jul 17.

44.

Presentation overrides specificity: probing the plasticity of alphaviral proteolytic activity through mutational analysis.

Lulla V, Karo-Astover L, Rausalu K, Merits A, Lulla A.

J Virol. 2013 Sep;87(18):10207-20. doi: 10.1128/JVI.01485-13. Epub 2013 Jul 17.

45.

Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout.

Gläsker S, Lulla A, Lulla V, Couderc T, Drexler JF, Liljeström P, Lecuit M, Drosten C, Merits A, Kümmerer BM.

Virol J. 2013 Jul 15;10:235. doi: 10.1186/1743-422X-10-235.

46.

Ebselen reduces the toxicity of mechlorethamine in A-431 cells via inhibition of apoptosis.

Lulla A, Pino MA, Piętka-Ottlik M, Młochowski J, Sparavalo O, Billack B.

J Biochem Mol Toxicol. 2013 Jun;27(6):313-22. doi: 10.1002/jbt.21490. Epub 2013 May 6.

PMID:
23649643
47.

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.

Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O'Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, Stahl MC, Maidment NT, Ritz B, Bronstein JM.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):636-41. doi: 10.1073/pnas.1220399110. Epub 2012 Dec 24.

48.

A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice.

Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, Rénia L, Ng LF.

J Immunol. 2013 Jan 1;190(1):259-69. doi: 10.4049/jimmunol.1202177. Epub 2012 Dec 3.

49.

Viperin restricts chikungunya virus replication and pathology.

Teng TS, Foo SS, Simamarta D, Lum FM, Teo TH, Lulla A, Yeo NK, Koh EG, Chow A, Leo YS, Merits A, Chin KC, Ng LF.

J Clin Invest. 2012 Dec;122(12):4447-60. doi: 10.1172/JCI63120. Epub 2012 Nov 19.

50.

Sequestration of G3BP coupled with efficient translation inhibits stress granules in Semliki Forest virus infection.

Panas MD, Varjak M, Lulla A, Eng KE, Merits A, Karlsson Hedestam GB, McInerney GM.

Mol Biol Cell. 2012 Dec;23(24):4701-12. doi: 10.1091/mbc.E12-08-0619. Epub 2012 Oct 19.

Supplemental Content

Support Center